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Summary
Background: Highly active antiretroviral therapy (HAART) containing didanosine
taken twice daily was compared with HAART containing didanosine taken once daily
in terms of adherence and efficacy.
Method: This was a self-controlled prospective cohort study, carried out in a tertiary
level hospital. A total of 49 HIV-infected patients were included. They were pre-
scribed HAART according to guidelines. After six months taking HAART containing
didanosine twice daily, patients continued with the same regimen of HAARTalthough
once daily. Thereafter they were followed up for a further nine months. Adherence
and virological efficacy were assessed at three-month intervals, for a total of six
times, in every patient.
Results: Overall, adherence was poor, with only 19 patients (39%) showing adequate
adherence for all six visits. Adequate adherence was observed in 29 patients (59%)
threemonths before didanosine switching, and in 37 patients (75%) threemonths after
didanosine switching (P = 0.034). Pooled HIV RNA results of the first three visits were
higher than the same results of the last three visits (P = 0.05).
Conclusions: Non-adherence is common among patients who take HAART. Simplifica-
tion of regimens is useful to improve adherence and efficacy.
# 2005 International Society for Infectious Diseases. Published by Elsevier Ltd. All
rights reserved.Introduction
The treatment of human immunodeficiency virus
(HIV) infection has evolved dramatically during* Corresponding author. Tel.: +34 964 726530;
fax: +34 964 726645.
E-mail address: brocav@meditex.es (B. Roca).
1201-9712/$30.00 # 2005 International Society for Infectious Diseas
doi:10.1016/j.ijid.2004.07.006recent years. Highly active antiretroviral therapy
(HAART) leads to the profound suppression of HIV
replication1 which in turn has resulted in declining
HIV-related morbidity and mortality rates.2
The success of HAART depends on the sustained
inhibition of viral replication. But the high cost, the
side effects, the large numbers of pills involved, and
complex dosing schedules of regimens results ines. Published by Elsevier Ltd. All rights reserved.
196 B. Roca et al.difficult adherence, which jeopardizes efficacy and
may promote the selection of drug-resistant HIV
strains.3
Studies have shown that adherence to HAART is
poor in clinical practice,4 and non-adherence is
considered the most important cause of treatment
failure in HIV infection.5 Drugs with fewer side
effects that are easier for patients to take can help
to improve adherence to HAART.
Didanosine, a nucleoside-analogue reverse-tran-
scriptase inhibitor (NRTI), is one of the first-line
components of HAART.5,6 The drug was traditionally
recommended to be employed twice daily, but side
effects, the large size of the tablets, and interac-
tions with food or other medications resulted in
significant inconvenience to patients, and clearly
favoured non-adherence.
Compared with the previous buffered formula-
tion, a recently developed enteric-coated formula-
tion of didanosine has several advantages for
patients: the daily dose can be prescribed in just
one pill,7 there are fewer interactions with food and
other medications,8,9 and side effects are less com-
mon.10 Thus, adherence with this new formulation
may be improved.
Some studies have found no differences in effi-
cacy between didanosine prescribed twice daily and
once daily.11—14 But no data are available on the
possible differences in adherence between these
two regimens of didanosine administration.
This study assessed the adherence and efficacy of
HAART regimens that contain didanosine, and com-
pared results in the same group of patients before
and after switching the drug from the previous
formulation administered twice daily to the new
enteric-coated formulation administered once
daily.Patients and methods
Study design and patients
This was an open-label, self-controlled study, car-
ried out in one group of patients. Participants were
adults recruited from the HIV Clinic of the Hospital
General of Castello´n (HGC), Spain.
According to 1998 guidelines,15,16 major inclusion
criteria were a CD4 cell count below 500 per mm3 or
HIV RNA plasma level above 20,000 copies/ml
before institution of therapy. Exclusion criteria
included a history of pancreatitis or peripheral
neuropathy, active alcohol or drug abuse,
hemoglobin < 9 g/dl, neutrophils < 1  109/L, pla-
telets < 50  109/L, creatinine > 2 mg/dl, biliru-
bin > 3 mg/dl, aspartate or alanine amino-transferase > five times the upper limit of normal,
and amylase > three times the upper limit of nor-
mal.
Treatment regimens and development of the
study
All participants began triple or quadruple combina-
tions that consisted of two buffered didanosine
tablets of 100 mg (or one tablet of 125 mg if weight
<60 kg) taken every 12 hours on an empty stomach,
plus one or two other NRTI, plus one protease
inhibitor or a non-nucleoside reverse-transcriptase
inhibitor (NNRTI) or abacavir. The combinations and
the doses of all medications were prescribed accord-
ing to recommendations of published guidelines,5,16
therefore, all regimens consisted of at least two
daily doses of medication other than didanosine.
The treatment ran from January 1998 to June
2000. Subjects who had taken other antiretroviral
treatments before were also included. From Decem-
ber 2000 to March 2001, when participants had
completed at least three visits, didanosine tablets
were switched to one daily enteric-coated capsule
of 400 mg (250 mg if weight <60 kg), taken on an
empty stomach. Throughout the study the other
drugs were continued without change. Follow-up
ended in April 2002 when every patient had made
at least three visits after switching didanosine regi-
men.
No concomitant treatment with other antiretro-
virals was allowed. Drugs that were contraindicated
with antiretrovirals of the different regimens were
not prescribed. Patients with absolute CD4 cell
counts <200/mm3 received prophylaxis against
Pneumocystis carinii.17 Patients received adherence
counseling throughout the study period.
Evaluation of patients
When treatment was initiated, demographic char-
acteristics and previous antiretroviral medications
were documented. Current medications not related
to HIV infection were also registered.
Patients were evaluated a total of six times,
every three months, i.e., six and three months
before switching didanosine formulation (months
6 and 3), at the time of didanosine switching
(month 0), and three, six and nine months after-
wards (months 3, 6 and 9). Fasting glucose, trigly-
ceride, cholesterol and other routine biochemistry
analysis, full blood count, CD4 cell count, and HIV
RNA level were determined at study entry and two
to four weeks before each visit. CD4 cell count was
assessed by flow cytometry, and viral load was
measured in plasma samples using a quantitative
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Table 1 Characteristics of the study patients.
Number of
patients (%)
Total 49 (100)
Gender
Male 42 (86)
Female 7 (14)
Age (mean  SD) 37  7 years
HIV risk behavior
Drug user 36 (73)
Homosexual 8 (16)
Heterosexual 4 (8)
Vertical 1 (2)
Hepatitis C virus
coinfection
37 (75)
Previously treated with
other antiretrovirals
39 (80)
Antiretrovirals other than didanosine taken by patients
throughout the study
Zidovudine 32 (65)
Nelfinavir 21 (43)
Stavudine 16 (33)
Indinavir 14 (29)
Efavirenz 11 (22)
Abacavir 2 (4)
Ritonavir 2 (4)PCR technique with a lower limit of detection of
20 copies/ml (Amplicor HIV, Roche Diagnostic Sys-
tems, Branchburg, NJ, USA) and transformed to
log10 values. Adherence, side effects, and efficacy
were specifically recorded at each visit.
Adherence was considered adequate when: (1)
patients kept their appointments, (2) they reported
more than 80% adherence to treatment, and (3) HIV
RNA level was at least 1.5 log10 below the pre-
treatment level. Adherence was considered inade-
quate when condition numbers 1 or 2 were not met
and adherence was considered indeterminate when
the first two conditions were met but condition
number 3 was not. Self-reported adherence (condi-
tion number 2) was assessed as follows: in every
visit, after a brief explanation regarding the diffi-
culties associated with perfect adherence, patients
were specifically asked: ‘‘what percentage of your
treatment have you really taken in the last three
months?’’ Similar methods of adherence assessment
have been used in other studies.18—20
For the purpose of this study the virological
efficacy of treatment was defined as the presence
of an HIV RNA level below detectable limits
(<20 copies/ml).20
Factors associated with adherence and
efficacy
The association of adequate adherence in all six
visits was assessed by using a multivariate approach
with the following factors: age, sex, antiretrovirals
other than didanosine, hepatitis C virus infection,
HIV risk behaviour, baseline (month 6) HIV RNA
level and baseline (month 6) CD4 cell count.
The association of virological efficacy for all six
visits was also assessed by using a multivariate
approach with the following factors: age, sex, anti-
retrovirals other than didanosine, hepatitis C virus
infection, HIV risk behaviour, and baseline (month
6) CD4 cell count.
Statistical analysis
A sample size of 45 patients was calculated to
provide a 70% likelihood of detecting at least a
16% improvement in the proportion of adherent
patients with the once-daily didanosine regimen,
at the a level of 0.05.
Differences before and after didanosine switch-
ing were analyzed with the McNemar’s test when
variables were discrete, and with the paired sam-
ples t-test when variables were continuous. The
possible association of adherence and efficacy with
the studied factors was analyzed with logistic
regression models.All reported P values were one-sided at the 0.05
significance level. An intention to treat analysis was
used in the study.Results
A total of 49 patients were included in the study.
Table 1 shows the characteristics of the partici-
pants, including sociodemographic data, prevalence
of hepatitis C virus coinfection, and any antiretro-
virals other than didanosine that patients were
taking. During follow-up, two participants were
changed to other modalities of HAART that did
not include didanosine, one at month 0 because
of high HIV RNA and the other at month 6 because
of amylase elevation. The remaining 47 patients
completed the six visits without changes to their
HAART. No AIDS-defining opportunistic infections
or deaths were registered among participants
during this study. A total of 46 patients (94%) had
received a didanosine regimen before commencing
this study.
Table 2 and Figure 1 show data on adherence
during the patients’ six visits. Adherence was clas-
sified as adequate or inadequate for 99% of visits.
The percentage of adherent patients was higher at
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Table 2 Adherence, CD4 cell count, and HIV RNA change throughout the study period.
Monthsa 6 3 0 3 6 9
Adherent patients (%)b 32 (65) 29 (59) 33 (67) 37 (75) 37 (75) 36 (74)
Number of patients with
virological efficacy (%)c
19 (41) 21 (47) 26 (55) 23 (54) 24 (61) 26 (67)
CD4 cells, /mm3, mean  SDc 508  285 462  268 545  317 546  303 506  253 483  268
HIV RNA, copies/ml,
log10, mean  SDc,d
2.16  1.58 2.19  1.62 1.94  1.56 1.81  1.47 1.61  1.40 1.68  1.47
a Months before and after switching didanosine formulation.
b n = 49 in all controls.
c n < 49 in all controls because of unavailable results of patients who did not keep their appointments.
d For undetectable HIV RNA levels, 0.5  1.3 log10 copies/ml was chosen, 1.3 log10 copies/ml (20 copies/ml) being the lower limit
of detection of the assay.
Figure 1 Adherence change throughout the study per-
iod.month 3 compared with month 3 (P = 0.034).
Pooled data for the first three visits compared with
pooled data for the last three visits also showed
improved adherence with the once-daily didanosine
formulation (P < 0.001).
Table 2 shows the immunologic and virologic
status of participants during the study period.
CD4 cell count remained fairly constant during fol-
low-up and no change was observed after didanosine
switching. On the other hand, HIV RNA was lower
after didanosine switching. Pooled data for the first
three visits compared with pooled data for the last
three visits showed lower HIV RNA with the once-
daily didanosine formulation (P = 0.05).
A total of 19 patients (39%) showed adequate
adherence for all six visits. A multivariate analysis
disclosed an association of adequate adherence in
all visits with higher basal CD4 cell count and with
HIV risk behaviour other than drug use. No associa-
tion was found with the other five analyzed factors.
A total of 15 patients (31%) showed virological
efficacy for all six visits.Discussion
Male gender and intravenous drug use predomi-
nated, not only among the study patients but also
among the whole cohort of patients who attended
the Castello´n General Hospital.21 Similar sociode-
mographic characteristics have been reported inHIV-infected patients in several other regions of
Spain.22
The assessment of adherence is problematic. A
variety of methods and surrogatemarkers have been
used for this purpose. Physician or nurse judgment is
unreliable, even with patients who are well known
to them. Individuals are often reluctant to admit
that they are not taking their medications, however,
when they admit that they are missing doses they
are usually telling the truth. Pharmacy records may
assist in appraising adherence. For example, when
patients collect their medication after a time inter-
val longer than that scheduled, non-adherence is
almost certain. Pill count may also be useful in some
settings, but it is not convenient in clinical practice.
Moreover, patients may easily manipulate the mea-
surement in several ways, and they must also
remember to bring the pill bottles to the hospital.
Pill bottles can now incorporate special caps with
an electronic device (MEMSCaps) that records when
the bottle is opened and so when the patient suppo-
sedly takes the medication. When properly used this
appliance can be an excellent day-to-day monitor of
adherence. Nevertheless, it is cumbersome for
patients and is not reliable when multiple doses
are removed from the bottle at the same time.
For now its role seems limited to research studies.
Drug level measurement also has limited worth.
Blood levels only identify whether patients have
taken their most recent dose. Moreover, variability
in drug absorption and metabolism among subjects,
as well as the interaction between medications,
pose difficulties in the interpretation of blood
levels.
Resistance tests may also be employed to assess
adherence. In a patient with high viral load for
whom HAART has been prescribed, the absence of
mutations in a genotypic assay may indicate non-
adherence. Similarly, in a patient with apparent
drug failure, the presence of a virus sensitive to
the prescribed medications in a phenotypic assay
may be due to non-adherence. Nevertheless, like
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mislabel patients with poor absorption of drugs as
non-adherents.
Given that a ‘gold standard’ for measuring adher-
ence will probably never exist, a combination of
several of the above methods is probably the best
strategy to use in clinical practice.23,24
With the method employed, were based on self-
reporting as well as on attendance at scheduled
visits and HIV RNA response, adherence could be
classified as either adequate or inadequate for most
patients. The results show that adherence was sub-
optimal in general, with only slightly more than one
third of patients showing adequate adherence for all
six visits. Similar results have been repeatedly
observed in the same cohort of patients and in many
others.4,25,26 Non-adherence is considered the main
cause of treatment failure and is also one of the
principal determinants of the unacceptably high
HIV-related morbidity and mortality that still exists
in the HAARTera.27 Such a discouraging reality high-
lights the importance of including the assessment
and management of non-adherence in routine clin-
ical practice.
The most relevant finding in this study is that
adherence to HAARTmay be improved by simplifying
the regimen. A small reduction in the number of
daily pills lead to a significant increase in adher-
ence. Other studies have reached similar conclu-
sions, not only in HIV infection,28 but also in other
chronic conditions.29 Although nowadays HAART
regimens are much more patient friendly than those
available only a few years ago, efforts are still
needed to find antiretrovirals that are easier to
take.30,31
Despite improved adherence, CD4 cell count did
not increase in patients after didanosine switching.
The likely explanation is that most participants had
taken other HAART regimens before enrolling in this
study. Because CD4 cell count recovery with HAART
is generally limited to 100—200 cells/mm3 and tends
to plateau with time, the possibility of a CD4 cell
count increase in the patients was probably lim-
ited.32
On the other hand, HIV RNA significantly
decreased after didanosine switching. Because the
antiviral activity of both didanosine formulations
seemed equivalent,7 improved adherence was the
most probable reason for increased virological effi-
cacy in the study patients. Other factors, such as
training or practice (meaning that after three visits
patients were better at taking pills) could also
influence the improved adherence and efficacy of
treatment in these patients.
Multivariate analysis showed an association
between adherence with high basal CD4 cell countand HIV risk behaviour (other than drug users) and an
association of efficacy with high basal CD4 cell
count. Similar results have been previously
reported,21,33 although discrepant results exist in
these fields.34 Due to the small sample size in this
study, the results of these multivariate analyses
must be interpreted with caution.
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